Despite over a decade of scrutiny and over 20 published reports from various countries, the degree to which *ATM*mutations lead to breast cancer in the general population remains unclear. Furthermore, the methodology of *ATM*mutation detection is still laborious and costly. Because the ATM protein kinase phosphorylates such a wide array of downstream targets, many pathways to oncogenesis are possible and largely unexplored. What seems clear is that: A-T heterozygotes are at a fourfold to fivefold increased risk of breast cancer, although confidence intervals are large; and the spectrum of *ATM*mutations is distinct for A-T families versus breast cancer cohorts. Only a handful of mutations have been identified in both A-T families and breast cancer cohorts. Missense mutations represent \<10% of mutations in A-T patients and \>80% in breast cancer cohorts. *ATM*missense mutations are also more common in some leukemias and lymphomas. Experimental data suggest that some missense mutations represent dominant interfering mutations \[[@B1]-[@B5]\]; however, clinical support for a dominant interfering model is minimal in family studies, suggesting either that the model is flawed or that penetrance of these mutations is very low. Histological classifications of breast cancer are largely grouped as genetically homogeneous models, although expression microarray data suggest otherwise. Other studies have associated *ATM*-SNPs with increased breast cancer risk; however, just three SNP haplotypes across the *ATM*locus include \~95% of a global population, and this must be factored into such association models. Without the benefit of mRNA analyses, of minigene experiments, of Maximum Entropy Scores, of site-directed mutagenesis or of functional assays of ATM activity, most \'missense\' mutations cannot be reliably distinguished from polymorphisms or from other types of mutations, such as splicing variants that lead to secondary stop codons. Our recent analyses have focused on two ATM missense mutations, 7271T\>G and IVS10-6T\>G. For each of these mutations, there are published functional data suggesting that they act as dominant interfering mutations, and epidemiological data suggesting a role in breast cancer. Some family studies of the 7271T\>G mutation suggest that it is a highly penetrant breast cancer susceptibility allele. However, its infrequency in the population means that its contribution to breast cancer risk is slight and it is possible that 7271T\>G represents only one of a diverse array of uncommon ATM mutations leading to increased cancer risk. We found that the frequency of the IVS10-6T\>G mutation was not increased in breast cancer cases as compared with controls. Furthermore, the evidence that IVS10-6T\>G is an A-T mutation is called into question by our recent evidence that, in the one known example of a homozygous IVS10-6T\>G individual with A-T, a homozygous mutation at 5644C\>T was also present (Purayidom and colleagues, submitted). Taken together, these studies suggest that whereas no single *ATM*mutation impacts significantly upon breast cancer risk, it may be possible to group mutations that do modulate risk for breast cancer based on their phenotypic effects. This group of patients might benefit substantially from a therapeutic approach to correct missense mutations.
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